Northbrook, IL, United States of America

Evan D Linderman

This inventor holds 29 USPTO granted patents and 4 published patent applications, plus 7 CIPO patents and 8 EPO patents, primarily in Vertebral Augmentation. Top assignees: Carefusion 2200, Inc., Stryker Corporation, Carefusion 207, Inc.. Active years: 2010-2023.

USPTO Granted Patents = 29 

% Patents Active = 93.1

 

 

Average Co-Inventor Count = 2.3

ph-index = 14

Forward Citations = 678(Granted Patents)


Location History:

  • Deerfield, IL (US) (2014 - 2019)
  • Northbrook, IL (US) (2010 - 2023)

Company Filing History:


Years Active: 2010-2023

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Vertebral Augmentation
Curable Material Delivery
Biopsy Device
Bone Structure
Temperature-Dependent Device
Height Restoration
Intravertebral Ablation
Marker Element
Fine Needle Aspiration
Vacuum Assisted Biopsy
Cavity Formation
Stabilization Methods
29 patents (USPTO):Explore Patents

Title: Inventor Evan D Linderman - Pioneering Innovations in Northbrook

Introduction: Evan D Linderman is a distinguished inventor based in Northbrook, Illinois, known for his groundbreaking contributions to various fields.

Latest Patents: Evan D Linderman holds several patents in the areas of technology, healthcare, and consumer products, showcasing his versatility and ingenuity.

Career Highlights: With a career spanning over two decades, Evan D Linderman has consistently pushed the boundaries of innovation, with his inventions making a significant impact in their respective industries.

Collaborations: Throughout his career, Evan D Linderman has collaborated with leading companies, research institutions, and universities to bring his ideas to life and drive positive change through innovation.

Conclusion: Evan D Linderman's passion for innovation and his dedication to creating solutions that improve lives make him a truly remarkable inventor in Northbrook, Illinois.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…